Legal & General Group
GALT icon

Legal & General Group’s Galectin Therapeutics GALT Stock Holding History

Legal & General Group’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.6K Buy
+4,662
New +$12.1K ﹤0.01% 3084
2025
Q2 		– Sell
-38
Closed -$46 – 3458
2025
Q1 		$46 Sell
38
-2,444
-98% -$3.43K ﹤0.01% 3375
2024
Q4 		$3.2K Hold
2,482
– – ﹤0.01% 3364
2024
Q3 		$6.83K Hold
2,482
– – ﹤0.01% 3339
2024
Q2 		$5.6K Buy
+2,482
New +$7.54K ﹤0.01% 3370
2021
Q2 		– Sell
-4,552
Closed -$10K – 3557
2021
Q1 		$10K Hold
4,552
– – ﹤0.01% 3376
2020
Q4 		$10K Hold
4,552
– – ﹤0.01% 3340
2020
Q3 		$12K Sell
4,552
-1,988
-30% -$5.57K ﹤0.01% 3155
2020
Q2 		$20K Sell
6,540
-338
-5% -$850 ﹤0.01% 3068
2020
Q1 		$13K Sell
6,878
-2,388
-26% -$5.81K ﹤0.01% 3077
2019
Q4 		$27K Buy
9,266
+1,600
+21% +$5.56K ﹤0.01% 3095
2019
Q3 		$28K Buy
7,666
+2,305
+43% +$8.33K ﹤0.01% 2995
2019
Q2 		$22K Buy
+5,361
New +$23.2K ﹤0.01% 3159

Other funds holding GALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Legal & General Group's GALT Position: Q2 2026 in Review

Legal & General Group opened a new position in Galectin Therapeutics (GALT) in Q2 2026: 4,662 shares worth $21.6K. The stake represents ﹤0.01% of the portfolio and ranks #3084 among its holdings. This is a return to the name: Legal & General Group previously reported a position in GALT as recently as Q1 2025.

Legal & General Group first reported a position in GALT in Q2 2019 and has held it in 13 quarters since. The position peaked at $28K in Q3 2019. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

  • Legal & General Group held 4,662 shares of Galectin Therapeutics worth $21.6K as of Q2 2026.
  • Galectin Therapeutics was a new Legal & General Group position in Q2 2026.
  • Galectin Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #3084 holding.
  • Legal & General Group first reported a position in Galectin Therapeutics in Q2 2019 and has held it in 13 quarters since.
  • Legal & General Group's Galectin Therapeutics position peaked at $28K in Q3 2019.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.